Genenta Science
GNTA
3 hedge funds and large institutions have $27K invested in Genenta Science in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.24% less ownership
Funds ownership: 0.26% → 0.02% (-0.24%)
92% less capital invested
Capital invested by funds: $332K → $27K (-$305K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$5.87K |
| 2 |
Morgan Stanley
New York
|
+$3.39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AU
Algebris (UK)
London,
United Kingdom
|
-$315K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$203 |
GNTA Hedge Fund Activity: Q2 2022 in Review
3 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Genenta Science (GNTA) for Q2 2022, worth a combined $27K — down 92% from $332K a quarter earlier.
Fund positioning in GNTA was balanced in Q2 2022: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $5.87K. The largest seller was Algebris (UK), exiting entirely with an estimated $315K sold.
- 3 institutional investors held Genenta Science (GNTA) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $27K of Genenta Science stock for Q2 2022, down 92% quarter-over-quarter.
- 1 fund opened new Genenta Science positions in Q2 2022 and 1 closed out, a net change of 0 holders.
- The largest Genenta Science buyer in Q2 2022 was UBS Group, an estimated $5.87K added.
- The largest Genenta Science seller in Q2 2022 was Algebris (UK), an estimated $315K sold.
Based on aggregated 13F filings for Q2 2022.